This startup develops advanced drug formulations to enhance existing medications. They improve drug performance, reduce side effects, and increase stability, leading to safer and more effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many existing medications have limitations in terms of effectiveness, stability, and side effects, hindering optimal patient outcomes. Traditional drug development pathways can be lengthy and costly.
Solution
Anziva Pharmaceuticals focuses on enhancing existing drugs using the 505(b)(2) regulatory pathway, which allows for faster and more cost-effective approvals by leveraging existing safety and efficacy data. The company develops advanced drug formulations to improve product performance, increase stability, and reduce side effects. Anziva is also developing New Therapeutic Entities (NTEs) to enhance existing market products.
Target Audience
The primary target audience includes patients who require safer and more effective treatments, as well as healthcare providers seeking improved pharmaceutical options.
Features
- Utilizes the 505(b)(2) regulatory pathway for faster drug approval
- Focuses on improving the effectiveness of existing drugs
- Develops formulations with enhanced stability
- Aims to reduce side effects associated with current medications
- Developing New Therapeutic Entities (NTEs)